Search

everythinglearnresearchcommunity

for

Search:↓

A 19-year-old is considering switching from topical to oral minoxidil to combat hair loss, despite concerns about increased body hair. They are currently using minoxidil, ketoconazole shampoo, and dutasteride, and are willing to accept the trade-off of more body hair for better scalp hair growth.

The user is documenting their hair regrowth journey using oral finasteride, topical minoxidil, ketoconazole, dermarolling, biotin shampoo, and rosemary oil. They are committed to maintaining this regimen to track progress.

The user is treating hair loss with 1mg finasteride every other day, daily topical minoxidil, and weekly derma rolling, and is considering using hair fibers for special occasions. There is a discussion about the initial shedding phase of minoxidil treatment and the importance of consistent photo conditions to track progress.

A user started using 5mg minoxidil daily and 0.5mg dutasteride every two days for hair loss, along with rosemary, castor, and pumpkin oil twice a week, and derma stamping once a week. They plan to track progress with photos and maintain hair length with clippers.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The user shared five months of progress using oral finasteride, topical minoxidil, and supplements like biotin, zinc, omega-3, and collagen. They noted encouraging results, while others suggested trying oral minoxidil or microneedling for potentially better outcomes.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

Amino acids like lysine, methionine, and cysteine may help with androgenetic alopecia when taken in high doses along with a DHT blocker. Users discuss combining these with treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses hair loss treatment using finasteride, with the user noting improvements in hair density but a recent decrease in vertex density. Suggestions include adding minoxidil, but the user avoids it due to its toxicity to cats and considers oral minoxidil instead.

A user's experience of gaining weight while taking Dutasteride, and suggestions on how to continue using it without the negative side effects, such as exercising and tracking calories or switching to Finasteride.

A user recommends a device from Amazon to apply minoxidil directly to the scalp without wasting it. Another user asks if it can be used with foam minoxidil.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

A user experienced hairline improvement after four weeks on 1.5mg dutasteride but had side effects like reduced libido and sensitive nipples. They plan to switch to finasteride to manage these side effects.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

The user reported significant hair regrowth using a topical treatment of 0.3% finasteride and 6% minoxidil, with noticeable progress in five months. The treatment is applied once daily, and the user experienced some initial shedding but no side effects.